Literature DB >> 24131672

Deoxyschizandrin, a naturally occurring lignan, is a specific probe substrate of human cytochrome P450 3A.

Jingjing Wu1, Yunfeng Cao, Yanyan Zhang, Yong Liu, James Y Hong, Liangliang Zhu, Guangbo Ge, Ling Yang.   

Abstract

To accurately predict the modifications done during metabolic processes by cytochrome P450 (P450) 3A enzyme, selecting substrates that best represent a broad range of substrate substitutions and that follow the Michaelis-Menten kinetic properties is highly necessary. In the present study, the oxidative pathways of deoxyschizandrin (DS), the most abundant lignan in Fructus Schisandrae fruit extract, were characterized with liver microsomes from human (HLM) and rat (RLM). Only one monohydroxylated metabolite 7(S)-hydroxylated metabolite (isoschizandrin, ISZ), was identified using liquid chromatography-mass spectrometry and nuclear magnetic resonance techniques. CYP3A4 and CYP3A5 were found to be the major isoforms involved in the monohydroxylation of DS. Also, the kinetic studies showed that DS hydroxylation obeyed Michaelis-Menten kinetics both in HLM and in RLM. However, the subsequent metabolism of ISZ was nearly nonexistent when DS was present. More importantly, the interactions between DS and three well characterized CYP3A probe substrates, testosterone (TST), midazolam (MDZ), and nifedipine (NIF), were studied. TST and MDZ were shown to compete with DS for the mutual binding site, causing Km to be increased. The presence of DS also lowered the binding affinities for MDZ and TST. However, DS showed only slight inhibitory effects on nifedipine (NIF) oxidation even though NIF was able to inhibit DS hydroxylation in a noncompetitive fashion. These results show that DS is a good representative substrate of MDZ and TST primarily due to their shared, large binding regions on CYP3A. Therefore, DS is an attractive candidate as a novel CYP3A probe substrate for predicting the metabolic modifications in CYP3A activity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24131672      PMCID: PMC6067378          DOI: 10.1124/dmd.113.053884

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  42 in total

Review 1.  Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver.

Authors:  K Ito; T Iwatsubo; S Kanamitsu; K Ueda; H Suzuki; Y Sugiyama
Journal:  Pharmacol Rev       Date:  1998-09       Impact factor: 25.468

2.  Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism.

Authors:  K E Kenworthy; S E Clarke; J Andrews; J B Houston
Journal:  Drug Metab Dispos       Date:  2001-12       Impact factor: 3.922

Review 3.  In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model.

Authors:  J B Houston; K E Kenworthy
Journal:  Drug Metab Dispos       Date:  2000-03       Impact factor: 3.922

4.  Hydroxyprolylserine derivatives JBP923 and JBP485 exhibit the antihepatitis activities after gastrointestinal absorption in rats.

Authors:  K X Liu; Y Kato; T I Kaku; T Santa; K Imai; A Yagi; T Ishizu; Y Sugiyama
Journal:  J Pharmacol Exp Ther       Date:  2000-08       Impact factor: 4.030

5.  Sigmoidal kinetics of CYP3A substrates: an approach for scaling dextromethorphan metabolism in hepatic microsomes and isolated hepatocytes to predict in vivo clearance in rat.

Authors:  L E Witherow; J B Houston
Journal:  J Pharmacol Exp Ther       Date:  1999-07       Impact factor: 4.030

6.  Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes.

Authors:  V A Eagling; J F Tjia; D J Back
Journal:  Br J Clin Pharmacol       Date:  1998-02       Impact factor: 4.335

7.  Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases.

Authors:  Yong Liu; Jacqueline Ramírez; Larry House; Mark J Ratain
Journal:  Drug Metab Dispos       Date:  2010-01       Impact factor: 3.922

Review 8.  Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring.

Authors:  Shu-Feng Zhou; Charlie Changli Xue; Xue-Qing Yu; Chunguang Li; Guangji Wang
Journal:  Ther Drug Monit       Date:  2007-12       Impact factor: 3.681

Review 9.  Probing the world of cytochrome P450 enzymes.

Authors:  Reginald F Frye
Journal:  Mol Interv       Date:  2004-06

10.  Contribution of the N-glucuronidation pathway to the overall in vitro metabolic clearance of midazolam in humans.

Authors:  Sylvie Klieber; Sébastien Hugla; Robert Ngo; Catherine Arabeyre-Fabre; Viviane Meunier; Freddy Sadoun; Olivier Fedeli; Martine Rival; Martine Bourrie; François Guillou; Patrick Maurel; Gérard Fabre
Journal:  Drug Metab Dispos       Date:  2008-02-06       Impact factor: 3.922

View more
  4 in total

1.  Metabolism profiling of amino-noscapine.

Authors:  Hua-Jun Qu; Yang Qian
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-12-20       Impact factor: 2.441

2.  Gomisin A is a Novel Isoform-Specific Probe for the Selective Sensing of Human Cytochrome P450 3A4 in Liver Microsomes and Living Cells.

Authors:  Jing-Jing Wu; Guang-Bo Ge; Yu-Qi He; Ping Wang; Zi-Ru Dai; Jing Ning; Liang-Hai Hu; Ling Yang
Journal:  AAPS J       Date:  2015-09-11       Impact factor: 4.009

3.  In Vitro Glucuronidation of Wushanicaritin by Liver Microsomes, Intestine Microsomes and Expressed Human UDP-Glucuronosyltransferase Enzymes.

Authors:  Xiaodan Hong; Yuanru Zheng; Zifei Qin; Baojian Wu; Yi Dai; Hao Gao; Zhihong Yao; Frank J Gonzalez; Xinsheng Yao
Journal:  Int J Mol Sci       Date:  2017-09-19       Impact factor: 5.923

Review 4.  A Comprehensive Review of the Main Lignan Components of Schisandra chinensis (North Wu Wei Zi) and Schisandra sphenanthera (South Wu Wei Zi) and the Lignan-Induced Drug-Drug Interactions Based on the Inhibition of Cytochrome P450 and P-Glycoprotein Activities.

Authors:  Feng Zhang; Jianxiu Zhai; Nan Weng; Jie Gao; Jun Yin; Wansheng Chen
Journal:  Front Pharmacol       Date:  2022-03-11       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.